A Phase III Randomized Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Sqamous Cell Carcinoma
Enrolling By Invitation
99 years or below
All
Phase
N/A
750 participants needed
1 Location
Brief description of study
The purpose of this study is to compare the effects of atezolizumab plus tiragolumab versus atezolizumab plus placebo or double placebo on subjects with esophageal cancer who have had at least 2 cycles of chemoradiotherapy without progression of their disease.
Subjects with unresectable, locally advanced esophageal cancer will receive either atezolizumab plus tiragolumab, atezolizumab plus placebo, or double placebo.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: esophageal cancer,cancer,unresectable
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 843911
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
